Composition Containing Extracts of the Fruit of Hovenia Dulcis THUNB as an Active Ingredient for Preventing and Treating Bone Diseases

Abstract

The invention relates to a composition containing extracts of the fruit of Hoveniadulcis Thunb ., gallocatechin, and methyl vanillate as active ingredients for preventing and treating bone disease. The extracts of the fruit of Hoveniadulcis Thunb ., the gallocatechin, and the methyl vanillate according to the present invention are natural materials and thus cause no side effects, and may activate the Wnt/β-catenin pathway to promote bone formation rather than inhibiting bone decomposition, and therefore may be effective in treating osteoporosis and related diseases. In addition, the extracts of the fruit of Hoveniadulcis Thunb ., the gallocatechin, and the methyl vanillate according to the present invention may have the effects regrowing hair and preventing and treating wounds and metabolic diseases related to the activation of Wnt/β-catenin pathway.

1 . A composition for the prevention and/or treatment of bone disease comprising  Hoveniadulcis Thunb . extract as an active ingredient. 
     
     
         2 . The composition for the prevention and/or treatment of bone disease according to  claim 1 , characterized in that the bone disease is any one selected from the group consisting of osteoporosis, osteomalacia, rickets, fibrous osteitis, aplastic bone disease and metabolic bone disease. 
     
     
         3 . The composition for the prevention and/or treatment of bone disease according to  claim 1 , characterized in that the extract promotes activity of a Wnt/β-catenin signaling pathway. 
     
     
         4 . The composition for the prevention and/or treatment of bone disease according to  claim 1 , characterized in that the extract promotes bone formation by activating a Wnt/β-catenin signaling pathway. 
     
     
         5 . The composition for the prevention and/or treatment of bone disease according to  claim 1 , characterized in that the bone disease is osteoporosis. 
     
     
         6 . The composition for the prevention and/or treatment of bone disease according to  claim 1 , characterized in that a dosage for the extract ranges from 0.1 to 10 g/kg. 
     
     
         7 . The composition for the prevention and/or treatment of bone disease according to  claim 1 , characterized in that the composition is administered via oral, parenteral, intraarterial, intradermal, transdermal, intramuscular, intraperitoneal, intravenous or subcutaneous routes. 
     
     
         8 . A health functional food for the improvement and/or alleviation of bone disease comprising  Hoveniadulcis Thunb . extract as an active ingredient. 
     
     
         9 . The health functional food for the improvement and/or alleviation of bone disease according to  claim 8 , characterized in that the bone disease is any one selected from the group consisting of osteoporosis, osteomalacia, rickets, fibrous osteitis, aplastic bone disease and metabolic bone disease. 
     
     
         10 . The health functional food for the improvement and/or alleviation of bone disease according to  claim 8 , characterized in that the extract promotes activity of a Wnt/β-catenin signaling pathway. 
     
     
         11 . The health functional food for the improvement and/or alleviation of bone disease according to  claim 8 , characterized in that the extract promotes bone formation by activating a Wnt/β-catenin signaling pathway. 
     
     
         12 . The health functional food for the improvement and/or alleviation of bone disease according to  claim 8 , characterized in that the bone disease is osteoporosis. 
     
     
         13 . A composition for the prevention and/or treatment of bone disease comprising a gallocatechin as an active ingredient. 
     
     
         14 . The composition for the prevention and/or treatment of bone disease according to  claim 13 , characterized in that the bone disease is any one selected from the group consisting of osteoporosis, osteomalacia, rickets, fibrous osteitis, aplastic bone disease and metabolic bone disease. 
     
     
         15 . The composition for the prevention and/or treatment of bone disease according to  claim 13 , characterized in that the gallocatechin promotes activity of a Wnt/β-catenin signaling pathway. 
     
     
         16 . The composition for the prevention and/or treatment of bone disease according to  claim 13 , characterized in that the gallocatechin promotes bone formation by activating a Wnt/β-catenin signaling pathway. 
     
     
         17 . The composition for the prevention and/or treatment of bone disease according to  claim 13 , characterized in that the bone disease is osteoporosis. 
     
     
         18 . The composition for the prevention and/or treatment of bone disease according to  claim 13 , characterized in that the composition is administered via oral, parenteral, intraarterial, intradermal, transdermal, intramuscular, intraperitoneal, intravenous or subcutaneous routes. 
     
     
         19 . A health functional food for the prevention and/or improvement of bone disease comprising a gallocatechin as an active ingredient. 
     
     
         20 . The health functional food for the prevention and/or improvement of bone disease according to  claim 19 , characterized in that the bone disease is any one selected from the group consisting of osteoporosis, osteomalacia, rickets, fibrous osteitis, aplastic bone disease and metabolic bone disease. 
     
     
         21 . The health functional food for the prevention and/or improvement of bone disease according to  claim 19 , characterized in that the gallocatechin promotes the activity of a Wnt/β-catenin signaling pathway. 
     
     
         22 . The health functional food for the prevention and/or improvement of bone disease according to  claim 19 , characterized in that the gallocatechin promotes bone formation by activating a Wnt/β-catenin signaling pathway. 
     
     
         23 . The health functional food for the prevention and/or improvement of bone disease according to  claim 19 , characterized in that the bone disease is osteoporosis. 
     
     
         24 . A composition for the prevention and/or treatment of bone disease comprising a methyl vanillate as an active ingredient. 
     
     
         25 . The composition for the prevention and/or treatment of bone disease according to  claim 24 , characterized in that the bone disease is any one selected from the group consisting of osteoporosis, osteomalacia, rickets, fibrous osteitis, aplastic bone disease and metabolic bone disease. 
     
     
         26 . The composition for the prevention and/or treatment of bone disease according to  claim 24 , characterized in that the methyl vanillate promotes the activity of a Wnt/β-catenin signaling pathway. 
     
     
         27 . The composition for the prevention and/or treatment of bone disease according to  claim 24 , characterized in that the methyl vanillate promotes bone formation by activating a Wnt/β-catenin signaling pathway. 
     
     
         28 . The composition for the prevention and/or treatment of bone disease according to  claim 24 , characterized in that the bone disease is osteoporosis. 
     
     
         29 . The composition for the prevention and/or treatment of bone disease according to  claim 24 , characterized in that the pharmaceutical composition is administered via oral, parenteral, intraarterial, intradermal, transdermal, intramuscular, intraperitoneal, intravenous or subcutaneous routes. 
     
     
         30 - 48 . (canceled) 
     
     
         49 . A health functional food for the prevention and/or improvement of bone disease comprising a methyl vanillate as an active ingredient.